Eva Chalas

Eva Chalas

Auto-generated profile, based on publicly available information

Eva Chalas

Department of Medicine, NYU Winthrop Hospital, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
JDJ. DeMuro
J. DeMuro
AHA. Hanna
A. Hanna
ECE. Chalas
E. Chalas
BCBárbara Cunha
Bárbara Cunha
The shoulder is the third most common site for bone and soft tissue tumours and limb-sparing resection for tumours of the shoulder girdle remains challenging.

1 March 1992 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ECEva Chalas
Eva Chalas
MWMarie Welshinger
Marie Welshinger
WEWilliam Engellener
William Engellener
JCJohn Chumas
John Chumas
RBRobert Barbieri
Robert Barbieri
WMWilliam J. Mann
William J. Mann

31 March 2008 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
AZAlla Zemlyak
Alla Zemlyak
SHSonya Hwang
Sonya Hwang
ECEva Chalas
Eva Chalas
CPColette R. J. Pameijer
Colette R. J. Pameijer

18 August 2017 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
PDF file
WPWilliam H. Parker
William H. Parker
JBJonathan S. Berek
Jonathan S. Berek
EPElizabeth A. Pritts
Elizabeth A. Pritts
DODavid Olive
David Olive
ECEva Chalas
Eva Chalas
DCDan Clarke-Pearson
Dan Clarke-Pearson

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
OROlivier Rixe
Olivier Rixe
VCVincent Castonguay
Vincent Castonguay
HCHenry Jacob Conter
Henry Jacob Conter
ECEva Chalas
Eva Chalas
PDPratibha Desai
Pratibha Desai
SFStephan Fiset
Stephan Fiset
Background: Maveropepimut-S (MVP-S) is a novel immunotherapeutic that educates a specific CD8 T cell response to the cancer antigen, survivin, to orchestrate immune-mediated elimination of survivin-expressing cancer cells. Specifically, MVP-S is a lipid-in-oil formulation of the DPX delivery platform, incorporating five survivin-specific immunogenic peptides, the innate immune stimulant, polydIdC, and a CD4 T cell helper peptide. In prior clinical studies, MVP-S and intermittent low-dose cyclophosphamide (CPA) elicited confirmed clinical responses (both partial and complete by RECISTv1.1) and induced a robust, durable survivin-specific CD8 T cell response. Moreover, the combination with pembrolizumab appeared to be well tolerated in solid tumors and lymphomas. The purpose of this phase 2 study is to explore whether this combination may be safe and effective in advanced, metastatic bladder cancer patients, both naïve to, and previously treated with, immune checkpoint inhibitors. Results: Seventeen (17) subjects were treated with the combination of MVP-S, CPA and pembrolizumab. Subjects received an average of 3 prior lines of therapy with 13/17 (76.4%) having previously received an anti-PD1/L1. Seven subjects progressed on or after anti-PD1/L1 as last line of therapy prior to entering the trial. The combination was well-tolerated, with majority of AEs being grade 1 or grade 2. Five (5) out of 17 subjects showed response: 3 subjects with PR (unconfirmed) and 2 with CR (confirmed). Three of these, including the 2 CRs, had progressed on anti-PD-1/L1. Long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17 months) and coincides with an increase in detectable survivin-specific T cells in peripheral blood. Conclusion: Preliminary data suggest that MVP-S/CPA and pembrolizumab is a well-tolerated combination and shows encouraging preliminary clinical activity in the treatment of advanced or metastatic bladder cancer patients, including patients who have progressed on prior anti-PD-1/L1 therapy. Citation Format: Olivier Rixe, Vincent Castonguay, Henry Conter, Eva Chalas, Pratibha Desai, Christian Squillante, Lisa A. MacDonald, Rebekah Conlon, Yogesh Bramhecha, Heather Hirsch, Jeremy R. Graff, Stephan Fiset. Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT035.

14 October 2019
Verified
Dataset
Closed access
ECEva Chalas
Eva Chalas
This is a comprehensive review of literature indicating a decreased risk of ovarian cancer in ever intrauterine device (IUD) users.